Floatz logo

L19IL2/L19TNF

Squamous Cell Carcinoma

Philogen S.p.A.UNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Neonc Technologies, Inc.
Phase 4BB
Cis-Diamminedichloroplatinum Ii
University of Oxford
Phase 3BB
Docetaxel
Hummingbird Bioscience
Phase 2BB
Oxaliplatin
University of Oxford
Phase 3BB
Fibrin Sealant
Oxford University Hospitals NHS Trust
Phase 4BB

View all 50 →

Same molecule, other indications

L19IL2/L19TNF is also rated in:

skin basal cell carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
cutaneous neuroendocrine carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
Kaposi's sarcomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →